Company news

EyePoint, Inc. news in 2020

EyePoint, Inc.'s news releases, calls and decks from 2020, newest first.

View company

EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation

December 17, 2020

EyePoint Pharmaceuticals Announces 1-for-10 Reverse Stock Split

December 7, 2020

EyePoint Pharmaceuticals Reports Positive Results from GLP Toxicology Study of EYP-1901, a Potential Six-month Treatment of Wet Age-related Macular Degeneration

December 2, 2020

EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4

November 18, 2020

EyePoint Pharmaceuticals Presents Positive Data of YUTIQ® and DEXYCU® in Four Poster Sessions at the American Academy of Ophthalmology 2020 Virtual Annual Meeting

November 15, 2020

EyePoint Pharmaceuticals Announces Presentations at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting

November 9, 2020

EyePoint Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Corporate Developments

November 4, 2020

EyePoint Pharmaceuticals Announces Third Quarter 2020 Financial Results Release Date and Conference Call Information

October 28, 2020

EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility Modifying 2020 and 2021 Revenue Covenants

October 7, 2020

EyePoint Pharmaceuticals Announces Preliminary Net Product Revenue for Third Quarter 2020

October 6, 2020

EyePoint Pharmaceuticals Secures New Purchase and Marketing Agreement with Vantage Outsourcing for DEXYCU®

August 23, 2020

EyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements

August 19, 2020

EyePoint Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Corporate Developments

August 4, 2020

EyePoint Pharmaceuticals Announces Second Quarter 2020 Financial Results Release Date and Conference Call Information

July 28, 2020

EyePoint Pharmaceuticals Expands Executive Leadership Team with the Appointment of Jay S. Duker, M.D., as Chief Strategic Scientific Officer

July 12, 2020

EyePoint Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Developments

May 5, 2020

EyePoint Pharmaceuticals Announces First Quarter 2020 Financial Results Release Date and Conference Call Information

April 28, 2020

EyePoint Pharmaceuticals Provides COVID-19 Pandemic Business Operations Update

March 31, 2020

EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Corporate Progress

March 4, 2020

EyePoint Pharmaceuticals Announces Positive Topline 36-month Follow-up Data for Second Phase 3 Study of YUTIQ®

March 1, 2020

EyePoint Pharmaceuticals Announces Fourth Quarter and Full-Year 2019 Financial Results Release Date and Conference Call Information

February 26, 2020

EyePoint Pharmaceuticals and Vision Center Network of America Sign Purchase Agreement for DEXYCU®

February 17, 2020

EyePoint Pharmaceuticals Signs Exclusive License Agreement with Equinox Science to Develop Tyrosine Kinase Inhibitor Vorolanib for the Treatment of Wet AMD, Diabetic Retinopathy and Retinal Vein Occlusion

February 2, 2020

EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize DEXYCU® for Post-operative Inflammation in Mainland China, Hong Kong, Macau and Taiwan

January 26, 2020

EyePoint Pharmaceuticals Announces Preliminary Fourth Quarter and Full-Year 2019 Revenues

January 22, 2020

Calls in 2020

Decks in 2020